Free lookups: 0/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
0 of 3 free lookups remaining Upgrade
New search Medicine profile Ebastine

Clinical medicine profile

Ebastine

Therapeutic agent (verify pharmacological class)

POM
Evidence state General guidance Reviewed 14 Aug 2026
Route
See product SmPC
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Hypersensitivity to the active substance or excipients.
  • Additional absolute contraindications are indication- and product-specific — consult SmPC.

Precautions

  • Obtain allergy and medication history.
  • Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs.
  • Use the lowest effective dose for the shortest appropriate duration.
  • Monitor for expected class adverse effects.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

10-20mg daily. A dose of 10mg /day should not be exceeded in case of hepatic failure.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

03 Clinical use

Use, effects & interactions

Indications

  • Allergic rhinnitis [seasonal and perennial]
  • idiopathic chronic urticaria Clinical selection for Ebastine should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Therapeutic agent (verify pharmacological class).
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • Adverse reactions vary by agent.
  • Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes).
  • Report suspected ADRs via national pharmacovigilance channels.
  • Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
  • Document allergy status and key interactions.
04 Pharmacology

Mechanism & disposition

An antihistamine with poor blood brain barrier penetration.

An antihistamine with poor blood brain bar…It is devoid of cholinergic and CNS side e…At receptor, enzyme, ion channel, transpor…
Read complete mechanism

An antihistamine with poor blood brain barrier penetration. It is devoid of cholinergic and CNS side effects Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.

Onset

Product-specific

Duration

Product-specific

Route

See product SmPC

Elimination

are product-specific. Consider food effects, protein binding, hepatic CYP/UGT

Half-life

when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

FromKES 384
MedianKES 456
Listings7
BrandManufacturerPackObserved price
EBAMIN 10MG TABLETS MEDCURE HEALTHCARE LTD Film-Coated Tablet 10MG Unavailable
EBAMIN SYRUP MEDCURE HEALTHCARE LTD Syrup Unavailable
EBASTINE Not recorded SYRUP 5MG/5ML 60ML(HISTY) KES 383.77Daima Chemist price-list reference ↗ Source date not recorded · verify current price
EROSTIN DAIMA BIASHARA / Wholesale Import SUSP 5MG/5ML 60ML KES 456.44Daima Chemist price-list reference ↗ Source date not recorded · verify current price
ERSOTIN 10 Micro Labs Ltd Tablet Unavailable
HISTY Not recorded TABS 20MG 10*S KES 456.88Daima Chemist price-list reference ↗ Source date not recorded · verify current price
HISTY SYRUP KRISHNA CHEMISTS LTD Oral Liquid Unavailable
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Professional class pharmacology (Therapeutic agent (verify pharmacological class))
Last reviewed14 Aug 2026
EvidenceGeneral guidance

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.